Prophylactic oral acyclovir in recurrent genital herpes

Area of Science:

• Virology
• Dermatology
• Infectious Diseases

Background:

• Genital herpes is a common sexually transmitted infection.
• Frequent recurrences significantly impact patients' quality of life.
• Limited effective long-term prophylactic options exist for recurrent genital herpes.

Purpose of the Study:

• To evaluate the efficacy of oral acyclovir as a prophylactic treatment for frequently recurring genital herpes.
• To compare recurrence rates and time to first recurrence between acyclovir and placebo groups.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 56 patients with recurrent genital herpes.
• Patients received oral acyclovir (200 mg four times daily) or placebo for 12 weeks.
• Recurrence rates and time to first recurrence were monitored.

Main Results:

• Acyclovir significantly reduced the mean monthly recurrence rate from 1.4 (placebo) to 0.05.
• Median time to first recurrence extended to 100 days with acyclovir, compared to 14 days with placebo.
• Recurrence rates became similar between groups after treatment cessation.

Conclusions:

• Prophylactic oral acyclovir is an effective treatment for reducing the frequency of genital herpes recurrences.
• Acyclovir demonstrates a significant delay in the time to the first herpes outbreak during treatment.
• The study supports the use of acyclovir for long-term management of severe recurrent genital herpes.